foxo4-dri senolytic peptide human trial 2024 Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells Peptide inhibitors targeting FOXO4-p53 interactions

"Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908202500947, for the corresponding incident on March 10, 2025, which is beyond the 30calendar day timeframe." FDA issued warning letters to three drug manufacturers, including the Canadian over-the-counter drugmaker Sante Manufacturing, for failing to adhere to CGMP requirements

The purchaser assumes all responsibility for secondary labeling, safety testing of final packaged goods, and regulatory compliance if repackaged for resale

the study physician attributed the death to pre-existing coronary artery disease unrelated to the drug, but the FDA's Pharmacy Compounding Advisory Committee cited this "unresolved cardiac signal" in December 2024 as a reason to keep the compound off the approved compounding list

Ingredients are sourced from carefully vetted, FDA-inspected facilities

This is not typically permanent